

July 29, 2025

Company Name	Otsuka Holdings Co., Ltd.
Name of Representative	Makoto Inoue President and Representative Director, CEO
Code Number	4578, Prime market of the Tokyo Stock Exchange
Contact	Yuji Kogure Director, Investor Relations Department (Phone: +81-3-6361-7411)

## Notice Regarding Revisions of Consolidated Results Forecast for the first half of FY2025

Otsuka Holdings Co., Ltd. (the “Company”) has revised its consolidated financial forecasts for the first half of FY2025 (January 1 - June 30, 2025), previously announced on February 14, 2025.

### 1. Revision of the consolidated financial forecasts for the first half of FY2025

	Revenue	Business profit	Operating profit	Profit before tax	Profit for the period	Profit attributable to owners of the Company	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast(A)	1,174,000	200,000	200,000	198,000	149,000	147,000	276.26
Revised forecast(B)	1,180,000	239,000	242,000	226,000	175,000	173,000	325.12
Amount of change(B-A)	6,000	39,000	42,000	28,000	26,000	26,000	
Change (%)	0.5%	19.5%	21.0%	14.1%	17.4%	17.7%	
(Reference) 1H FY2024 Actual	1,108,930	213,622	126,279	142,195	110,625	107,795	198.61

### 2. Reasons for the revision

Due to the favorable business performance during the current interim consolidated accounting period, we have revised the forecast announced on February 14, 2025 upward.

Despite the impact of yen appreciation, revenue remained robust, particularly in the pharmaceutical business. In pharmaceutical business, in addition to the antipsychotic drug *Rexulti* positioned as a growth driver in the 4th MTMP, the long-acting injection *ABILIFY MAINTENA* and the V<sub>2</sub>-receptor antagonist *JYNARQUE* are driving performance. In nutraceutical business, *POCARI SWEAT* in Japan and *EQUELLE* have shown strong performance. On the other hand, Selling, general and administrative expenses, as well as R&D expenses, are expected to be lower than initially planned.

As a result, revenue, business profit, operating profit, profit for the period, and profit attributable to owners of the Company are all expected to exceed the previously announced forecasts.

The Company plans to announce the consolidated financial forecast for the full fiscal year ending December 2025 in conjunction with the financial results announcement on July 31, 2025.



Note: The above forecasts are based on information available and assumptions deemed reasonable by the Company at the time of this announcement. Actual operating results may differ from these projections due to various factors.